August 23, 2019
Roche/Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab) gained Japanese regulatory approval on August 22 for the treatment of small cell lung cancer (SCLC), becoming the first immune checkpoint inhibitor to carry this indication in the country. The thumbs-up was given for...read more